Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237481 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)
A Phase 3 study, sponsored by Heron Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 418
- Enrollment target
NCT03237481: Completed Phase 3 study, sponsored by Heron Therapeutics.
NCT03237481 is a Phase 3 study that has completed, run by Heron Therapeutics. The registered enrollment target is 418 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03237481, a Phase 3 study, has completed, sponsored by Heron Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 418 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration into the surgical site in subjects undergoing unilateral open inguinal herniorrhaphy.
Primary Outcome
Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720. The prescribed activity for NRS-A is sitting up from a resting position.
Interventions
- DRUG Saline placebo
- DRUG HTX-011
- DEVICE Vial access device
- DRUG Bupivacaine HCl
- DEVICE Luer-lock applicator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2017-07-31 |
| Est. Completion | 2018-01-16 |
| Phase | Phase 3 |
What the finished NCT03237481 record still lists
NCT03237481 is an interventional study that assigns participants to a tested intervention. The registered 418 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 5 interventions - of which Saline placebo is the first listed.
NCT03237481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03237481 about?
NCT03237481 is a clinical study titled "Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)". This is a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration into the surgical site in subjects undergoing unilateral open inguinal herniorrhaphy.
What is the current status of trial NCT03237481?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 418 participants. The study started on 2017-07-31. Estimated completion is 2018-01-16.
What interventions are being tested in trial NCT03237481?
The interventions under investigation include: Saline placebo (DRUG), HTX-011 (DRUG), Vial access device (DEVICE), Bupivacaine HCl (DRUG), Luer-lock applicator (DEVICE).
Who is sponsoring clinical trial NCT03237481?
This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03237481's enrollment target sits among peer trials
418 900th of 2000 higher than 1,099 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI